Abstract Purpose: Malignant glial brain tumors consistently overexpress neurokinin type 1 receptors. In classic seed-based brachytherapy, one to several rigid 125 I seeds are inserted, mainly for the treatment of small low-grade gliomas. The complex geometry of rapidly proliferating high-grade gliomas requires a diffusible system targeting tumor-associated surface structures to saturate the tumor, including its margins. Experimental Design: We developed a new targeting vector by conjugating the chelator 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid to Arg 1 of substance P, generating a radiopharmaceutical with a molecular weight of 1,806 Da and an IC 50 of 0.88 F 0.34 nmol/L. Cell biological studies were done with glioblastoma cell lines. neurokinin type-1 receptor (NK1R) autoradiography was done with 58 tumor biopsies. For labeling, 90
Y was mostly used. To reduce the ''cross-fire effect'' in critically located tumors, 177 Lut and 213 Bi were used instead. In a pilot study, we assessed feasibility, biodistribution, and early and long-term toxicity following i.t. injection of radiolabeled 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid substance P in 14 glioblastoma and six glioma patients of WHO grades 2 to 3. Results: Autoradiography disclosed overexpression of NK1R in 55 of 58 gliomas of WHO grades 2 to 4. Internalization of the peptidic vector was found to be specific. Clinically, the radiopharmeutical was distributed according to tumor geometry. Only transient toxicity was seen as symptomatic radiogenic edema in one patient (observation period, 7-66 months). Disease stabilization and/or improved neurologic status was observed in 13 of 20 patients. Secondary resection disclosed widespread radiation necrosis with improved demarcation. Conclusions: Targeted radiotherapy using diffusible peptidic vectors represents an innovative strategy for local control of malignant gliomas, which will be further assessed as a neoadjuvant approach.
Histologic differentiation, the degree of tumor cell infiltration into adjacent normal brain tissue and variable growth rates (1 -3), determines mean survival in primary malignant gliomas, which varies between nearly 10 years in low-grade oligodendroglioma WHO II (4) and 10 to 14 months in highly proliferative glioblastoma (5, 6) . Survival differences and response to therapy are regulated by genetic factors (7) . Despite technological advances in diagnosis and treatment, prognosis of malignant gliomas remains unchanged (8) . With regard to low-grade gliomas that affect a younger age group, there is considerable variability in diagnostic criteria over time (9) and in deciding when and how to initiate treatment. The fact that brain-intrinsic neoplasms represent the second most frequent cancer-related cause of death in adolescents and younger adults between the age of 15 and 35 after leukemias (10) underscores the need for innovative treatment strategies.
Because 95% of glioblastomas manifest as unifocal lesion that recur within a 2-cm margin at the primary site (11), loco-regional drug application has become a therapeutic option, using bifunctional molecules that consist of a targeting domain [e.g., the transferrin receptor (12) , the interleukin-4 and interleukin-13 receptors (13, 14) , or a monoclonal antibody against tenascin-C ( 15 -17) ] and of an effector domain [e.g., bacterial toxins (12 -14) or radioisotopes (18) ]. Toxin-delivering conjugates have to target every single tumor cell; radionuclide-based approaches can eliminate receptornegative tumor cells and cells not directly targeted by the drug through the range-dependent ''cross-fire'' effect. Most protocols for targeted local therapy of malignant brain tumors administer macromolecular compounds given by convection-enhanced delivery to improve biodistribution (13) (19, 20) , relapsing medulloblastoma (21) , and SSTR2-positive gliomas (22) ]. However, inconsistent expression of SSTR2 limited application in glioblastoma. We, therefore, developed a new bifunctional peptidic vector that targets the neurokinin type-1 receptor (NK1R), which is consistently overexpressed in primary malignant gliomas (23) . Its major ligand substance P (SP) belongs to the family of tachykinin peptide neurotransmitters (24) . Besides physiologic expression on distinct interneuron populations of the afferent spinal pain and the limbic system, NK1 receptors have been detected only at restricted sites within the central nervous system (e.g., on reactive mammalian astrocytes in lesions of multiple sclerosis; ref . 25) . We conjugated the chelator 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid (DOTAGA; ref. 18) to Arg 1 of the linear 11-mer peptide SP, generating a radiopharmaceutical with a molecular weight of 1,806 Da (DOTAGA-Arg 1 -SP). Following preclinical assessment, we conducted a pilot study in 20 patients with gliomas of WHO grades 2 to 4 to primarily assess biodistribution and short-term and long-term toxicity and to assess as secondary end points the clinical and radiological responses.
Materials and Methods
Human glioma cells LN319 (26, 27) were grown to a confluence of 80% to 90% in standard conditions (28) . Oregon Green 488 fluorescent SP (SP-OG, Invitrogen AG, Basel, Switzerland) was used at 100 nmol/L for the time course studies. Concentration dependence was determined after 6 hours of incubation. Unlabeled SP (10 Amol/L) was added for competitive blocking of the receptor-mediated uptake of SP-OG. Transfections and flow cytometry studies have been done to assess ligand internalization and the effect on cell cycle and apoptosis. SP receptor was overexpressed in LN319 cells, using the DNA fragment that encodes the long splice variant of the human receptor (Genbank accession no. NM_001058). PCR amplification was carried out using Pfu DNA Polymerase (Promega, Madison, WI) and primers with an EcoRI restriction site at the 5 ¶ and an XhoI site at the 3 ¶ end (5 ¶_NK1R_EcoRI, 5 ¶-GTGCGGAATTCGCCACCATGGATAACGTCCTCC; 3 ¶_NK1R_XhoI, 5 ¶-GAACCGCTCGAGGGAGAGCACATTGGAGGAGAA). The PCR product was cloned into the pcDNA3 eukaryotic expression vector (Invitrogen). Fixed cells were analyzed with a FACScan flow cytometer and CellQuest software (Becton Dickinson, Franklin Lakes, NJ), counting at least 50,000 events. Cell cycle and apoptosis were investigated using propidium iodide and Annexin V-FITC (BD Biosciences, Allschwil, Switzerland), respectively. Propidium iodide was used at 10 Ag/mL.
Receptor autoradiography. Surgical specimens consisting of 34 glioblastomas, 9 oligodendrogliomas II/III, and 15 astrocytomas II/III were obtained after surgical resection and processed as described (23, 29) . Receptor density was quantified using 125 I-Bolton-Hunter-SP and a cutoff of at least twice the value estimated for the nonspecific binding (29, 30) . The IC 50 value for Lu-DOTAGA-SP at the NK1R was determined in competition experiments with successive tumor tissue sections.
Radioconjugates. Chemical synthesis of the radiopharmaceutical is described. The peptides were assembled on solid phase with a semiautomatic peptide synthesizer (RinkCombichem Technologies, Bubendorf, Switzerland) using fluorenylmethoxy-carbonylpolyamide solid-phase peptide synthesis (31 Bi required an additional cleaning step using a Sep-Pak C18 cartridge (Waters, Milford, MA). The solution was immobilized on the cartridge, washed with 10 mL of a 0.4 mol/L sodium acetate buffer (pH 5), and eluted with 10 mL methanol. After evaporation, a radiochemical purity of about 90% was achieved. For injection, the solution was diluted to a volume of 1 mL with 0.9% NaCl.
Patients. The clinical data of the 20 patients enrolled into the study are shown in Table 1 . The protocol had been approved by the Ethical Committee of the University Hospitals of Basel. Response criteria as proposed by Macdonald were applied (34) . Patients with high-grade lesions (n = 16) were included following progression or denial of conventional treatment options. The four low-grade glioma patients selected targeted radiotherapy instead of an observational phase or external beam radiotherapy. Patients were evaluated weekly for the first month and thereafter according to the course of the disease. Functional status was assessed using the Barthel index.
Injection of the radiopharmaceutical. In all cases, injection of the drug has been done via an implanted catheter system (16, 22, 35) , either into the tumor or into the resection cavity. The catheter itself is connected to a s.c. port, which is punctured for the injection of the drug. Preparation of the patient with 20 mg dexamethasone and, immediately before injection, 60 g of the osmodiuretic drug mannitol leads to a transient and very efficient reduction of the i.t. pressure that allows to inject the radiopharmaceutical against low resistance as previously described (22) . Before injection of the active compound, the system is flushed with 1.5 mL of human albumin 5% over 1 minute to coat the plastic surface. Thereafter, the active drug is injected in a volume of 2 mL over 1 minute. Finally, the system is flushed again with 1.5 mL of human albumin 5% over 1 minute.
Positron emission tomography, single photon emission-tomography, and perfusion computed tomography. Positron emission tomography was done following standard protocols after application of [ 99m Tc]Neurolite (Bristol-Myers Squibb, Billerica, MA) as a marker for brain perfusion. Three SPECT scans were done after each administration of the radiopharmaceutical; scan duration was 30 minutes with continuous acquisition on a dual-head camera (Picker P2000, Philips Medical Systems, Eindhoven, the Netherlands). Scans were acquired with a medium-energy collimator in multiple energy windows to distinguish between Stability and biodistribution of DOTAGA-Arg 1 -SP. For all patients except for cases 9, 10, 11, and 18, planar scintigraphic images were obtained with a large field-of-view camera (DIACAM; Siemens Medical) as described (22, 35) . In these cases, tumor dosimetry was estimated according to the published protocol (22) . Due to large error ranges of at least F20% (22), we developed a novel approach to measure the tumor dose that allows an individual three-dimensional voxelwise dosimetry by fusing therapeutic SPECT images with the tumor images 9 as shown for patients 9, 10, 11, and 18. In this trial, dosimetry data could only be calculated for cases 10 The chemical integrity of the radioligand in blood, cerebrospinal fluid, and resection cavity fluid was examined as described. HPLC (Bischoff HPLC System, Metrohm AG, Herisau, Switzerland) and a radioactivity detector (LB509 Radioflow Detector, Berthold Technologies GmbH, Regensdorf, Switzerland) were used. Stabilities were tested using radiolabeled substance in a concentration of 1.8 Amol/L in 500 AL cerebrospinal fluid and 100 AL 0.1 mol/L Ca-diethylenetriaminepentaacetic acid at 37jC. After incubation, aliquots of 100 AL were 9 In preparation. 
Results
Incidence of NK1R and binding affinity of DOTAGA-SP. Thirty-two of 34 glioblastomas (94%), 7 of 9 oligodendrogliomas II/III, and 15 of 15 astrocytomas overexpressed NK1R (Fig. 1A) ,
NK1-, NK2-, and NK3-selective ligands allowed classification of the SP-binding sites as NK1R (Fig. 1A) . Background radioactivity was below 5%. 29; Fig. 1B) .
Receptor-mediated uptake of SP conjugates. Flow cytometric analysis revealed bright staining of LN319 glioblastoma cells following incubation with 100 nmol/L SP-OG (EC 50 = 30 nmol/L). Coincubation with 10 Amol/L of unlabeled SP resulted in a 90% block of SP-OG internalization (Fig. 1C) . Overexpression of NK1R full-length cDNA in LN319 glioblastoma cells by transient transfection accelerated the kinetics of SP-OG internalization compared with nontransfected cells, not 90 Y]-DOTAGA-SP is only 1 to 2 minutes due to rapid degradation and renal clearance, distinct from tubular reuptake as known for octreotide-based peptidic vectors (22) . Twenty-four-hour urine samples showed that 60% to 70% of the locally injected radioactivity had been excreted. The remaining activity was confined to the target site as shown on whole body scans. Only in the urinary bladder and in the kidneys, faint signals were obtained in whole-body scintigrams, which were slightly above background radioactivity levels. All other organs were negative on whole-body scintigrams during the 72 hours of observation period. Diffusibility of [
111 In]-DOTAGA-SP is shown by marking a glioblastoma satellite lesion 4 hours following i.t. injection ( Fig. 2A) . DOTAGA-SP in glioblastomas. In 14 glioblastoma, local injections of radiolabeled DOTAGA-SP were done (Table 1) (Fig. 2A) . Absence of drug-related toxicity and objective responses encouraged expansion of this approach to another 12 glioblastoma patients. Impaired neurologic function improved in 5 of 14 glioblastoma patients (cases 4, 7, 9, 11, and 12) within 2 weeks after initiation of targeted radiotherapy (Table 1) , a phenomenon not detectable during external beam radiotherapy. In cases 4, 6 (callosal nodule, see above), 12, and 13, radiolabeled DOTAGA-SP was directly injected into the nodular tumor without previous surgery, which allowed to directly assess the effects on the targeted tumor. Two such cases are highlighted (cases 4 and 12). In case 12, a large left-sided thalamic glioblastoma in a 45-year-old woman with increased i.c. pressure, right-sided hemiparesis, and aphasia was only (Fig. 2B) . In case 4 pretreated with external beam radiotherapy (54 Gy) and temozolomide chemotherapy, 1,125 MBq [
177 Lu]-DOTAGA-SP were injected into a progressive pontine glioblastoma via a transcerebellar catheter without side effects. Clinical (15-70, Barthel index) and radiologic improvement lasted for 5 months. In cases 3 and 7, surgical debulking was done after targeted radiotherapy, which disclosed extensive radiation necrosis. As secondary end points, we assessed survival after initiation of targeted radiotherapy and overall survival (Table 1 ). In glioblastoma, median survival after initiation of this local treatment was 11 months (range, 6-24 months), and median overall survival was 16 months (range, 7-26 months).
DOTAGA-SP in malignant gliomas WHO grades 2 and 3. To assess intermediate and long-term toxicity, two anaplastic gliomas WHO grade 3 and four low-grade gliomas WHO grade 2 were included (Table 1) . Impaired neurologic function markedly improved in two of these six patients (cases 15 and 18) within 2 weeks after the injection of the radiopharmaceutical ( Table 1) . Because of critical tumor location in case 18, the less energetic [ 177 Lu]-DOTAGA-SP was used. Except for the anaplastic astrocytoma patient (case 18) that died from tumor progression, the remaining five patients could be evaluated for signs and symptoms of intermediate or longterm toxicity. No toxicity was noticed within a median observation period of 26 months (range, 14-66 months). This is important because the peptidic vector DOTAGA-SP is diffusible, and low amounts of NK-1 receptors are expressed at restricted sites in the mammalian central nervous system. In cases 16 to 20, surgical resection was done following i.t. (cases 18, 19, and 20) and intracavitary (cases 16 and 17) administration, which disclosed widespread radiation necrosis. In case 19, the initially nonenhancing hypodense lesion demarcated as a perifocal ring-enhancing structure with central hypodensity and de novo peripheral calcification, suggestive for radiation necrosis according to perfusion CT imaging (Siemens software; Fig. 3D and E) . Craniotomy became necessary 27 months following i.t. injection of DOTAGA-SP due to signs of i.c. pressure requiring steroid medication. Surgery was considerably facilitated due to improved demarcation of margins (Supplementary Video). Histologic work-up disclosed a calcified, completely radionecrotic lesion. Table 1 due to large error ranges. The functional status of the patients has been assessed using the Barthel index at initiation and 3 months after completion of targeted radiotherapy (37) . Temporary improvement or stabilization was observed in 13 cases and gradual worsening in the remaining seven cases due to incomplete tumor control (Table 1) . Transient perifocal edema reaction was controlled with corticosteroids. Secondary edema reaction was accompanied by a minor and transient paresis of the distal left arm in case 19 (Fig. 3B ).
Discussion
The fact that 95% of malignant gliomas clinically manifest as unifocal lesions that also recur at the primary site (11) underscores the need for local therapies as one essential pillar of glioma treatment. Several bifunctional biomolecules, consisting of a targeting and an effector domain (12 -17) , have been developed. Intratumoral and/or intracavitary injection of the diffusible vector DOTAGA-SP represents a versatile new tool for the local control of malignant gliomas. Chelated peptides can be labeled with different radioisotopes with distinct chemico-physical properties. Saturation of the irregular structure of glioblastomas may best be achieved with a diffusible targeting system, as shown by marking a tumor satellite lesion ( Fig. 2A) . In addition, the ''cross-fire'' effect of h-emitting radionuclides allows to treat receptor-negative tumor cells and areas not sufficiently saturated by the drug. Conjugated SP showed high affinity to NK1R of brain tumor tissue, and the ligand showed specific uptake and internalization (Fig. 1) (22, 35) had several drawbacks, which could be overcome by this new targeting system: (a) the cognate SP receptor NK1R is overexpressed in virtually all glial neoplasms, whereas expression of SSTR2 is low in most glioblastomas (29, 35, 38, 39) ; (b) NK1R expression in normal brain tissue is restricted to circumscribed areas, whereas SSTR2 are ubiquitously expressed, not allowing precise autoradiographic distinction between normal brain tissue and tumor cells in areas of tumor cell infiltration (35, 38) ; (c) strong expression of NK1R within the tumor neovasculature (23) suggests concomitant targeting of vascular structures; (d) labeling kinetics of the chelator DOTAGA (40) conjugated to SP are superior to DOTA (reaction rate, 10-fold higher) suitable for labeling with the a-particle emitter Bi-213; and finally, (e) first experience with DOTAGA-SP resulted in stronger clinical and radiologic responses compared with the prototypical sstr2 targeting system (22, 35) . We have selected a peptidic vector that is stable at the target site for up to 72 hours but gets rapidly degraded within 1 to 2 minutes upon entry into systemic circulation due to serum peptidases. This minimizes the risk of systemic side effects from NK-1 expressing immune cells and from unspecific kidney problems due to tubular reuptake of the radiopharmaceutical (41) . Unambiguous clinical and radiological responses were observed in cases of monotherapy with DOTAGA-SP, for instance, a partial response was seen in a large thalamic glioblastoma (case 9; Fig. 2B ), accompanied by marked functional amelioration. Partial and lasting neurologic recovery was also seen in cases 4, 7, 11, 12, 15, and 18 following targeted radiotherapy. Case 4 represents a unique report of a locally treated progressive brainstem glioblastoma, which showed objective clinical and radiologic responses for 5 months. Thus far, only a few experimental reports have been published on brainstem gliomas in rodent models (42) . Local therapies are generally used following tumor debulking to enhance tumor control at the resection rim (17, 43) . In addition, i.t. application is also being investigated (44) . The small drug-like vector DOTAGA-SP can either be injected into the resection cavity or directly into the tumor mass. In seven cases, DOTAGA-SP was directly injected into the tumor, whereas it was applied into the resection cavity in the remaining 14 cases. Neoadjuvant application of radiolabeled DOTAGA-SP as first-line treatment before resection has been done in two low-grade gliomas (cases 19 and 20) , which was well tolerated. Eight primary or secondary lesions had been resected following i.t. injection of radiolabeled DOTAGA-SP, histologically showing extensive radiation necrosis. Surgery was found to be considerably facilitated (Supplementary Video) because of a better demarcation of tumor margins and a reduction of intraoperative bleeding as a result of radiation effects on the tumor vasculature (23) . The maximum range of 90 Y is only 12 mm. This means that radiation alone without a process of biodistribution cannot explain the histologic finding of radiation necrosis. This finding at the tumor periphery several centimeters distant from the site of injection suggests a rapid process of diffusion of the low molecular weight compound DOTAGA-SP to mainly contribute to local biodistribution of the radiopharmaceutical, which may also be supported by a slower process of convection.
Late radiation necrosis with mass effect and functional deterioration has frequently been observed following interstitial radiotherapy using 125 I seeds (45) . In the neoadjuvant approach (i.e., targeted h-radiotherapy) followed by surgical debulking, induction of extensive radiation necrosis represents one of the goals of treatment. If a glioma is not resectable due to critical location, low-range h-and/or a-emitters should be used to minimize collateral neurologic damage, as done for cases 1, 4, 15, 16, and 18. 177 Lu and 213 Bi have a maximum range of 1.5 and 0.06 mm, respectively, compared with 12 mm of 90 Y. Therapeutic a-protocols may be best suited for invasive tumor cells beyond visible tumor margins. We always conducted secondary resection of irradiated large and accessible tumors. During the observational phase, interpretation of a new enhancing ring-like structure can be difficult, especially in low-grade gliomas. In these cases, perfusion CT was found to be useful to differentiate hypovascular radionecrosis from vital neoplastic tissue ( Fig. 3D and E) . De novo ring-like calcification indicates radiation necrosis ( Fig. 3C and F) , which was histologically proven by lesion resection 26 months after DOTAGA-SP treatment (Supplementary Video). As mentioned above, surgery was significantly facilitated by pretreating the lesion with this targeted approach, which created a sharply demarcated calcified lesion with reactive glial reaction. Normally, identification of tumor boarders when resecting a not-pretreated low-grade glioma is virtually impossible.
In conclusion, targeted radiotherapy using the radiolabeled diffusible peptidic vector DOTAGA-SP represents an innovative strategy for local control of malignant gliomas of WHO grades 2 to 4, which will be further examined for i.t. and intracavitary injections in future clinical trials.
